The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
The cut-off value of serum prostate-specific antigen (PSA) level in prediction of bone metastases and the correlation of serum PSA with the clinical stage, grade, score and the rate of bone metastases have been investigated in cases of prostate cancer (PCa). The study population consisted of 160 patients with histologically proven PCa between April, 1993 and August, 1996. The negative predictive value and the sensitivity were the highest (94%) in patients with a serum PSA value less than 10 ng/ml. We claim that in patients with PSA values less than 10 ng/ml whole body bone scan is not necessary.
Ataus
S
S
Department of Urology, Cerrahpasa School of Medicine, Istanbul University, Turkey.
Citçi
A
A
Alici
B
B
Onder
A U
AU
Sönmezoğlu
K
K
Erözenci
A
A
Solok
V
V
D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000556:secondary*; D005188:False Negative Reactions; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen